Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 14/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606096 | 0.84 | CASP3 (0.55) | CASP3POLBPYGLCASP7CASP9 | |
| SCHEMBL6607128 | 0.82 | CASP3 (0.53) | CASP3 | |
| SCHEMBL6606162 | 0.82 | CASP3 (0.52) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL6610883 | 0.78 | HPGDS (0.53) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL6610749 | 0.77 | ADAM17 (0.48) | CASP3 | |
| SCHEMBL6607173 | 0.77 | CASP3 (0.52) | CASP3NPC1 | |
| SCHEMBL12983653 | 0.76 | POLB (0.54) | POLBGAANPC1RAB9AMEN1 | |
| SCHEMBL7747532 | 0.76 | CASP3 (0.80) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL9829600 | 0.75 | NAALAD2 (0.54) | POLBGAANPC1RAB9AMEN1 | |
| SCHEMBL6609651 | 0.75 | HDAC8 (0.51) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163208-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6632962-B2 | N-(2-carboxy-1-haloacetylethyl)arylamide derivatives as inhibitors of caspase and cellular apoptosis. | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-14 | — | — | US | disclosed |
| US-20020132833-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-09-19 | — | — | US | disclosed |
| EP-1163208-A4 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1163208-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001010383-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132833-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP7 | CASP3 2/4885POLB 3179/4885PYGL 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.